The Latest Breaking News from Pfizer

Eligible people include those aged 75 and over, and anyone aged five and over who has a weakened immune system

Around five million people in total are eligible for a booster until the end of June.

Gilead Sciences and Pfizer join amicus brief

Pfizer’s Albert Bourla is among the CEOs who signed a letter against suspending mifepristone, citing its impact on the FDA and the biotech industry.

The pharmaceutical firm said it is confident the jabs for cancer could be ready by the end of the decade

Experts hope new vaccines will be ready by end of decade

Exclusive: Pharmaceutical firm says groundbreaking jabs could save millions of lives

The vaccine has been approved for use in children age between six months and four years old

Recent banking turmoil and rising interest rates have weighed heavily on investors’ sentiment lately. However, weak economic data signaling slowing growth could result in relatively easy monetary policies in the second half of 2023. Given the macroeconomic backdrop, investors could consider adding fundamentally sound low P/E stocks Pfizer (PFE), Chevron…